Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015
Latest action · Mar 27, 2015 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMar 24, 2015
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015
This bill requires the Government Accountability Office (GAO) to study whether generic versions of certain complex drugs or certain biological drugs face significantly different challenges in meeting the approval standards of the Food and Drug Administration (FDA) than generic versions of small-molecule drugs. (Complex drugs and biological drugs can be composed of large molecules that are more difficult to fully characterize than small molecules, so it can be more difficult to demonstrate that generic versions of these drugs are the same as the brand name versions.)
If the GAO determines that these generic drugs face significantly different challenges, then the GAO must also determine: (1) the evidence that should be required to demonstrate that one of these generic drugs is sufficiently similar to the brand name drug in safety, composition, and activity; (2) whether the Federal Food, Drug, and Cosmetic Act should be amended to address the approval of these generic drugs; and (3) whether the FDA should develop a policy document on the evidence that is necessary to obtain approval of these generic drugs.Cosponsors 7
Members who signed on, in the order they did. Signatures ran from Mar 24, 2015 to Nov 19, 2015; 3 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-NE | Brad Ashford | Original | Mar 24, 2015 |
| D-NC | G. K. Butterfield | Original | Mar 24, 2015 |
| R-FL | Gus M. Bilirakis | Original | Mar 24, 2015 |
| R-KS | Mike Pompeo | May 1, 2015 | |
| R-IL | Adam Kinzinger | May 21, 2015 | |
| R-NC | Richard Hudson | Nov 5, 2015 | |
| R-NY | Chris Collins | Nov 19, 2015 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Mar 24, 2015 |
| Health Subcommittee | Referred Mar 27, 2015 |
Actions 3
Everything that happened, newest first.
- Mar 27, 2015Referred to the Subcommittee on Health.
- Mar 24, 2015Introduced in House
- Mar 24, 2015Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 161, no. 49, March 24, 2015, page H1901.
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To require a study by the Government Accountability Office (GAO) to assess the Food and Drug Administration's current regulatory pathway for reviewing generic versions of nonbiologic complex drug products, and for other purposes.
- Short Titles as Introduced
- Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Mar 24, 2015Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.